Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in
Metastatic Renal Cell Carcinoma: Lessons for the Era of
Immunotherapy

J 2024

Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy

BÜCHLER, Tomáš a Alexandr POPRACH

Základní údaje

Originální název

Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy

Autoři

BÜCHLER, Tomáš (203 Česká republika) a Alexandr POPRACH (203 Česká republika, domácí)

Vydání

Targeted Oncology, Dordrecht, Springer, 2024, 1776-2596

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.400 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s11523-023-01031-y

UT WoS

001155895200001

Klíčová slova anglicky

Metastatic Renal Cell Carcinoma; Tyrosine Kinase Inhibitor Therapy

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 8. 2024 07:16, Mgr. Tereza Miškechová

Anotace

V originále

Several regimens combining immunotherapy and tyrosine kinase inhibitors (TKIs) have recently been validated for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). While immunotherapy is typically discontinued after 2 years in patients who neither progress nor experience limiting toxicity, according to the protocols of most recent phase III clinical trials, TKIs are to be continued until disease progression or the emergence of limiting toxicity. However, the prolonged use of TKIs is associated with significant toxicity and financial costs. This has sparked considerable debate about whether TKIs can be safely discontinued, particularly in mRCC patients who have achieved a verified complete response. This concise review examines the available evidence on TKI discontinuation in the context of mRCC management.

Návaznosti

NU21-03-00539, projekt VaV

Název: Vliv stresu endoplazmatického retikula na imunitní stav nádorů a účinnost imunoterapie při léčbě ovariálního a renálního karcinomu

Investor: Ministerstvo zdravotnictví ČR, Vliv stresu endoplazmatického retikula na imunitní stav nádorů a účinnost imunoterapie při léčbě ovariálního a renálního karcinomu, Podprogram 1 - standardní

Citovat

BÜCHLER, Tomáš a Alexandr POPRACH. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy. Targeted Oncology. Dordrecht: Springer, 2024, roč. 19, č. 2, s. 175-180. ISSN 1776-2596. Dostupné z: https://dx.doi.org/10.1007/s11523-023-01031-y.

@article{2423259,
   author = {Büchler, Tomáš and Poprach, Alexandr},
   article_location = {Dordrecht},
   article_number = {2},
   doi = {http://dx.doi.org/10.1007/s11523-023-01031-y},
   keywords = {Metastatic Renal Cell Carcinoma; Tyrosine Kinase Inhibitor Therapy},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy},
   url = {https://link.springer.com/article/10.1007/s11523-023-01031-y},
   volume = {19},
   year = {2024}
}

TY  - JOUR
ID  - 2423259
AU  - Büchler, Tomáš - Poprach, Alexandr
PY  - 2024
TI  - Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
JF  - Targeted Oncology
VL  - 19
IS  - 2
SP  - 175-180
EP  - 175-180
PB  - Springer
SN  - 17762596
KW  - Metastatic Renal Cell Carcinoma
KW  - Tyrosine Kinase Inhibitor Therapy
UR  - https://link.springer.com/article/10.1007/s11523-023-01031-y
N2  - Several regimens combining immunotherapy and tyrosine kinase inhibitors (TKIs) have recently been validated for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). While immunotherapy is typically discontinued after 2 years in patients who neither progress nor experience limiting toxicity, according to the protocols of most recent phase III clinical trials, TKIs are to be continued until disease progression or the emergence of limiting toxicity. However, the prolonged use of TKIs is associated with significant toxicity and financial costs. This has sparked considerable debate about whether TKIs can be safely discontinued, particularly in mRCC patients who have achieved a verified complete response. This concise review examines the available evidence on TKI discontinuation in the context of mRCC management.
ER  -

BÜCHLER, Tomáš a Alexandr POPRACH. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy. \textit{Targeted Oncology}. Dordrecht: Springer, 2024, roč.~19, č.~2, s.~175-180. ISSN~1776-2596. Dostupné z: https://dx.doi.org/10.1007/s11523-023-01031-y.

Podrobný výpis o publikaci